#USA #Nashville #Revance #Teoxane RHA® #Mepivacaine

Revance Introduces Teoxane RHA® Collection with Mepivacaine

Revance, a rapidly growing player in the global aesthetics and skincare market, has launched the Teoxane RHA® Collection, incorporating the innovative anesthetic mepivacaine. This significant advancement represents the first noteworthy change in anesthetic options for hyaluronic acid fillers in almost 20 years, replacing traditional lidocaine with mepivacaine in the U.S. market.

A Breakthrough in Anesthetic Innovation

The decision to integrate mepivacaine into the Teoxane RHA® Collection underscores Revance’s commitment to improving patient experiences during aesthetic procedures. Mepivacaine is not new to the medical field; it has been used in therapeutic contexts for over six decades. This long history of safe use reassures both practitioners and patients alike.

Unlike lidocaine, mepivacaine entails less local vasodilation, thereby minimizing common injection site reactions, such as bruising. Clinical studies affirm that the rheology and overall performance of fillers remain unchanged, while also maintaining effective pain control. This is backed by thorough preclinical and clinical evaluations that pitted RHA fillers containing mepivacaine against those with lidocaine, showing promising equivalency in effectiveness and safety.

Enhancing Patient Comfort

Valérie Taupin, the Founder and CEO of Teoxane, proclaimed, “The development of the Teoxane RHA® Collection with Mepivacaine exemplifies our steadfast commitment to innovation.” With the integration of mepivacaine, Teoxane aims to minimize the discomfort associated with filler injections, thereby enhancing the overall patient journey in aesthetic treatments.

Revance's CEO, Jeff Bedard, shares similar sentiments, emphasizing the importance of advancing patient experience without compromising on treatment outcomes. He regards the launch of the RHA® Collection with mepivacaine as a pivotal development that aligns with the company’s ethos of innovation and patient-centered care.

The Future of Aesthetic Medicine

The Teoxane RHA® Collection has received FDA approval in 2023, standing out for its exclusive patent by Teoxane for dermal fillers. Alongside the RHA® Collection, Revance offers an array of products that meet patient needs in aesthetics, including DAXXIFY® and SkinPen®, a leading microneedling device.

With distribution channels extending across 60 countries, Revance is positioned to address evolving requirements in the healthcare market. Their portfolio reflects a mix of innovative treatments while emphasizing skin science at every life stage. This strategic growth facilitates continual exploration of new markets, ensuring that patients worldwide can enjoy cutting-edge skincare solutions.

Conclusion

The introduction of mepivacaine in the Teoxane RHA® Collection marks a transformative shift in the aesthetic landscape. By prioritizing patient comfort and safety, Revance is paving the way for future innovations in aesthetic medicine. Individuals seeking aesthetic procedures can look forward to a more pleasant and effective experience, making the Teoxane RHA® Collection a game changer in the field. For more information, visit rha.revanceaesthetics.com.